immutep : immutep’s leading position within the lag-3 competitive landscape, 04 may 2021
Published 3 years ago • 481 plays • Length 7:58Download video MP4
Download video MP3
Similar videos
-
2:07
exploring lag-3 immunotherapy in cancer treatment: a life science animation & immutep collaboration
-
6:25
immutep (asx:imm, nasdaq:immp) discusses a transformative year for lag-3 therapies
-
11:22
latest from lag 3 and imm and outlook for 2022
-
12:28
immutep (asx:imm, nasdaq:immp) ceo marc voigt provides an update on clinical trials
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
25:01
side effects of immunotherapy
-
17:30
18 minutes with immutep ceo marc voigt
-
15:49
immutep (asx:imm) - webinar presentation
-
0:36
lag-3: a promising biomarker in cancer
-
3:33
immutep (asx:imm) reports positive trial data
-
10:01
immutep limited (asx:imm, nasdaq:immp) encouraging results for immutep's cancer therapies
-
5:58
how long to continue immunotherapy
-
0:51
embark on the journey of a comprehensive art solution with ri integra 3™ micromanipulator.
-
2:43
immunotherapy trials and hyperprogressive disease
-
2:54
what is the optimal duration of immunotherapy?
-
2:19
immunotherapy: what you need to know
-
2:30
impassion130: immunotherapy for tnbc
-
4:58
immp stock immp immutep top stocks to buy now
-
2:10
unmet needs and role of immunotherapy in stage 3 nsclc
-
0:50
research into new immunotherapies for breast cancer
-
7:13
from the helm: immutep's (asx:imm) executive director & ceo marc voigt